| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADAMTS9 |
| Uniprot No | Q9P2N4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 293-643aa |
| 氨基酸序列 | RFVEVLVVADNRMVSYHGENLQHYILTLMSIVASIYKDPSIGNLINIVIVNLIVIHNEQDGPSISFNAQTTLKNFCQWQHSKNSPGGIHHDTAVLLTRQDICRAHDKCDTLGLAELGTICDPYRSCSISEDSGLSTAFTIAHELGHVFNMPHDDNNKCKEEGVKSPQHVMAPTLNFYTNPWMWSKCSRKYITEFLDTGYGECLLNEPESRPYPLPVQLPGILYNVNKQCELIFGPGSQVCPYMMQCRRLWCNNVNGVHKGCRTQHTPWADGTECEPGKHCKYGFCVPKEMDVPVTDGSWGSWSPFGTCSRTCGGGIKTAIRECNRPEPKNGGKYCVGRRMKFKSCNTEPCL |
| 预测分子量 | 46.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ADAMTS9重组蛋白的3篇示例参考文献(注：文献为示例性概括，实际引用请核实原始论文)：
---
1. **标题**: *"ADAMTS9 Recombinant Protein Suppresses Tumor Metastasis via Extracellular Matrix Remodeling"*
**作者**: Zhang Y, et al.
**摘要**: 研究证实重组ADAMTS9蛋白通过降解细胞外基质成分(如聚集蛋白聚糖)抑制肿瘤细胞迁移，并降低体内转移模型的侵袭性，提示其潜在抗肿瘤作用。
2. **标题**: *"Functional Characterization of Recombinant ADAMTS9 in Cardiovascular Development"*
**作者**: Smith JL, et al.
**摘要**: 利用哺乳动物细胞表达系统获得重组ADAMTS9.发现其通过调控VEGF信号通路参与血管生成，基因敲除小鼠模型显示胚胎期血管发育异常。
3. **标题**: *"Structural Insights into ADAMTS9 Protease Activity Using Recombinant Protein Domains"*
**作者**: Brown KE, et al.
**摘要**: 通过表达ADAMTS9的催化结构域重组蛋白，结合晶体学分析揭示其底物识别机制及金属蛋白酶活性依赖的pH敏感性。
---
**建议**：具体文献可通过PubMed或Google Scholar以关键词“ADAMTS9 recombinant protein”“ADAMTS9 expression”检索，并筛选涉及蛋白表达、功能或结构研究的论文。
**Background of ADAMTS9 Recombinant Protein**
ADAMTS9 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 9) is a member of the ADAMTS family of secreted zinc-dependent proteases, known for their roles in extracellular matrix (ECM) remodeling, cell adhesion, and proteolytic processing of bioactive molecules. Structurally, ADAMTS9 contains a conserved metalloproteinase domain, a disintegrin-like module, a thrombospondin type-1 repeat (TSR), and a unique C-terminal ancillary domain. These features enable its interaction with ECM components and modulate enzymatic activity.
ADAMTS9 is implicated in diverse physiological processes, including organogenesis, angiogenesis, and connective tissue homeostasis. It cleaves proteoglycans like versican and aggrecan, regulating ECM integrity and cellular signaling. Notably, ADAMTS9 exhibits anti-angiogenic and anti-tumorigenic properties, partly through suppressing VEGF and Wnt/β-catenin pathways. Genetic studies link ADAMTS9 mutations to developmental defects, metabolic disorders, and cancers, highlighting its functional significance.
Recombinant ADAMTS9 protein is engineered for research to study its biochemical activity, structure-function relationships, and therapeutic potential. Produced in mammalian or insect cell systems, it often includes tags (e.g., Fc or His tags) for purification and detection. Researchers use it to investigate ECM dynamics, cell-matrix interactions, and disease mechanisms, such as fibrosis or tumor metastasis. Challenges in its production include maintaining proper folding and post-translational modifications critical for enzymatic function.
Current studies focus on elucidating ADAMTS9’s regulatory mechanisms, substrate specificity, and crosstalk with signaling pathways. Its recombinant form serves as a tool for drug discovery, biomarker development, and regenerative medicine, underscoring its dual role as a key ECM modulator and a potential therapeutic target.
×
